Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications
| Brand name | TRI-LO-SPRINTEC |
| Generic name | NORGESTIMATE AND ETHINYL ESTRADIOL |
| Distributed by / for | Teva Pharmaceuticals USA, Inc |
| NDC | 0093-2140-62 |
| Full product label | Tri-Lo-Sprintec (norgestimate and ethinyl estradiol) tablets USP - triphasic regimen, packaged in carton containing 3 Blister Cards, 28 Tablets Each, Rx only, Teva Pharmaceuticals USA, INC, North Wales, PA 19454, NDC 0093-2140-62 |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Distribution | USA nationwide. |
| Quantity | 92,676 cartons |
| Recall initiated | 2024-03-07 |
| Report date | 2024-04-03 |
| Recall completed | 2025-03-06 |
| Recall number | D-0428-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗